Pharmaceutical clinical study to accelerate FDA approval of SmartTrack

Aptar Announces Clinical Validation Study to Accelerate US FDA Approval of SmartTrack™ In-Vitro-in-Silico Platform for Pressurized Metered-Dose Inhalers

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Apr 16, 2025-

Pharmaceutical clinical study to accelerate FDA approval of SmartTrack

CRYSTAL LAKE, Ill. – AptarGroup, a global leader in drug and consumer product dosing, dispensing and protection technologies, today announces the commencement of a clinical study to validate its proprietary SmartTrack platform. The platform was developed by Aptar’s drug services company, Nanopharm. If validated, SmartTrack aims to reduce the need for clinical studies in generic drug product approvals by proving it can accurately predict clinical…